| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS158342 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts56 |
| Applications： | Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox and cowpox viruses. It was not assigned to a Dales EM category (Dales, et al, 2003), but was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location D5, an ATPase required for DNA replication. |
| Biosafety Level： | 2 BSL 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 7473, was isolated from the IHD-W strain of Vaccinia by S. Dales. The IHD-W strain was derived from an IHD-J strain of Vaccinia. |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This vaccinia mutant, originally designated plaque isolate no. 7473, was isolated from the IHD-W strain of Vaccinia by S. Dales, presumably by mutagenesis with nitrosoguanidine followed by replication in the presence of bromodeoxyuridine. It was not assigned to a Dales EM category (Dales, et al, 2003), but was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location D5, an ATPase required for DNA replication. Shifting infection conditions from permissive to non-permissive temperature (39.5 C) results in an abrupt cessation of DNA synthesis, described as a "fast stop" phenotype.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox and cowpox viruses. |
| Effect on Host： | Cytopathic effects in culture include cell enlargement and rounding, followed by death and sloughing CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: BSC-40 (ATCC CRL-2761) Recommended Host: BSC-40 (ATCC CRL-2761) Alternate Host(s): MRC-5, BS-C-1, HeLa, LLC-MK2 |
| Growth Conditions： | 1-3 days at 31 C with 5% CO2 |
| Name of Depositor： | S. Dales, R. Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS158342 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts56 |
| Applications： | Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox and cowpox viruses. It was not assigned to a Dales EM category (Dales, et al, 2003), but was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location D5, an ATPase required for DNA replication. |
| Biosafety Level： | 2 BSL 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 7473, was isolated from the IHD-W strain of Vaccinia by S. Dales. The IHD-W strain was derived from an IHD-J strain of Vaccinia. |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This vaccinia mutant, originally designated plaque isolate no. 7473, was isolated from the IHD-W strain of Vaccinia by S. Dales, presumably by mutagenesis with nitrosoguanidine followed by replication in the presence of bromodeoxyuridine. It was not assigned to a Dales EM category (Dales, et al, 2003), but was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location D5, an ATPase required for DNA replication. Shifting infection conditions from permissive to non-permissive temperature (39.5 C) results in an abrupt cessation of DNA synthesis, described as a "fast stop" phenotype.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox and cowpox viruses. |
| Effect on Host： | Cytopathic effects in culture include cell enlargement and rounding, followed by death and sloughing CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: BSC-40 (ATCC CRL-2761) Recommended Host: BSC-40 (ATCC CRL-2761) Alternate Host(s): MRC-5, BS-C-1, HeLa, LLC-MK2 |
| Growth Conditions： | 1-3 days at 31 C with 5% CO2 |
| Name of Depositor： | S. Dales, R. Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
